This page is specifically addressed to health professionals. Please follow these simple steps in order to assess the oral carcinoma risk score of your patients based on Studium Genetics proprietary technology (Oral Carcinoma Risk Algorithm, SG-OCRA™). You can order the collection kit from our distributors, please get in touch with our sales department writing an email to sales@studiumgenetics.com. What's in the box: Together with the collection kit you will receive from the distributor: The cost of the collection kit is not inclusive of the analysis of the sample. This will be invoiced to you separately by the laboratory (see point…
Research supporting the revolutionary method developed and patented by Studium Genetics for the assessment of the patient's risk of developing an Oral Squamous Cell Carcinoma (OSCC) has been published in top international peer-reviewed journals. Gissi, D. B., Suàrez-Fernandez, C., Rossi, R., Vitali, F., Marzi Manfroni, A., Gabusi, A., Morandi, L., Balbi, T., Montebugnoli, L., Foschini, M. P., & Tarsitano, A. (2024). Direct healthcare costs of oral cancer: A retrospective study from a tertiary care center. Journal of Cranio-Maxillofacial Surgery. https://doi.org/10.1016/j.jcms.2024.03.002 Gissi DB, Rossi R, Lenzi J, Tarsitano A, Gabusi A, Balbi T, Montebugnoli L, Marchetti C, Foschini MP, Morandi L.
Studium Genetics has developed and patented the Oral Carcinoma Risk Algorithm (SG-OCRA™) method for the early detection of patients at risk to develop Oral Squamous Cells Carcinoma (OSCC) and its precursor, high grade dysplasia, by quantitative DNA methylation analysis using bisulfite Next Generation Sequencing (NGS) in exfoliating brushes of oral mucosa. The markers involved in this invention are a set of 13 genes in which the aberrant methylation pattern is indicative of severe dysplasia and/or OSCC The DNA methylation analysis of 13 genes is eventually used to perform a calculation by using an internally developed and patented algorithm that generates…
Studium Genetics s.r.l. p.IVA 04039021201 PHONE +39 051 032 1925 EMAIL info@studiumgenetics.com ADDRESS via F. Petrarca 2 40136 Bologna (Italy)
Oral squamous cell carcinoma (OSCC) is a major public health challenge with more than 745,000 cases reported worldwide by IARC. Despite treatment modalities including surgery, radiotherapy and chemotherapy, the 5-year mortality rate remains approximately 60%. In addition, the development of a second primary OSCC after surgery ranges from 17% to 30% and is higher than any other tumor type and is the leading cause of cancer-related death. In current clinical practice, oral cancer screening is performed solely by visual inspection by general practitioners or dentists. In cases of suspicious lesions, patients are referred to oral and maxillofacial surgeons for further…
“Three researchers from the University of Bologna have developed a technology that enables early diagnosis of oral cancer. A noninvasive and painless system that also has potential applications related to prognosis and follow-up with a strong social impact. – Forbes, Italian edition, August 2022 Great advances in personalized medicine are revolutionizing the approach to the patient. In particular, the development of next-generation drugs, methods of early diagnosis, correct prognosis, prediction of efficacy, and personalized therapy represent a new frontier in medicine. Oral carcinoma remains one of the most aggressive cancers worldwide, with a 50% mortality rate within the first 5 years…
